Table 4.
Treatments ever used at relapse, at the discretion of the treating clinician
| Standard of care | Standard of care plus zoledronic acid | Standard of care plus docetaxel | Standard of care plus zoledronic acid and docetaxel | ||
|---|---|---|---|---|---|
| Patients with progression | 761 | 374 | 315 | 318 | |
| Reported new treatment | 671 (88%) | 303 (81%) | 260 (83%) | 257 (81%) | |
| Reported (new) life-extending treatment | 383 (50%) | 172 (46%) | 139 (44%) | 136 (43%) | |
| Life-extending treatment | |||||
| Docetaxel | 313 (41%) | 136 (36%) | 44 (14%) | 49 (15%) | |
| Abiraterone | 177 (23%) | 72 (19%) | 89 (28%) | 88 (28%) | |
| Enzalutamide | 66 (9%) | 18 (5%) | 25 (8%) | 26 (8%) | |
| Cabazitaxel | 26 (3%) | 14 (4%) | 22 (7%) | 30 (9%) | |
| Radium-223 | 6 (1%) | 1 (0%) | 6 (2%) | 3 (1%) | |
| Other treatments | |||||
| Anti-androgens | 512 (67%) | 234 (63%) | 181 (57%) | 174 (55%) | |
| Zoledronic acid | 128 (17%) | 50 (13%) | 35 (11%) | 36 (11%) | |
| Dexamethasone | 104 (14%) | 42 (11%) | 39 (12%) | 29 (9%) | |
| Diethylstilbestrol (also known as stilboestrol) | 84 (11%) | 43 (11%) | 38 (12%) | 41 (13%) | |
| Prednisolone | 72 (9%) | 22 (6%) | 28 (9%) | 23 (7%) | |
| Other chemotherapy* | 26 (3%) | 17 (5%) | 21 (7%) | 15 (5%) | |
| Other bisphosphonate† | 22 (3%) | 3 (1%) | 8 (3%) | 5 (2%) | |
| Strontium | 12 (2%) | 3 (1%) | 2 (1%) | 4 (1%) | |
| Cox-2 inhibition | 0 (0%) | 1 (0%) | 0 (0%) | 0 (0%) | |
*
Not docetaxel or cabazitaxel.
†
Not zoledronic acid